2’-O-MOE-U-3’-phosphoramidite

2’-O-MOE-U-3’-phosphoramidite

This product is a uridine nucleoside building block featuring a 2’-O-methoxyethyl (MOE) modification and a 3’-phosphoramidite group for automated solid-phase oligonucleotide synthesis. The MOE modification enhances nuclease resistance, binding affinity, and pharmacokinetic properties, making it especially used in antisense oligonucleotide (ASO) and RNA therapeutic development.

Key Features and Benefits:

• 2’-O-MOE Modification: Improves nuclease stability and enhances RNA binding affinity.

• Uridine Base: Preserves native pyrimidine pairing for biological compatibility.

• 3’-Phosphoramidite: Compatible with automated DNA/RNA synthesis workflows.

• High Purity: HPLC-purified, suitable for therapeutic oligonucleotide synthesis.

• Enhanced Pharmacokinetics: Supports improved in vivo half-life and efficacy.

Applications:

• Antisense Oligonucleotides (ASOs): Widely used for therapeutic oligo design.

• siRNA and RNA Therapeutics: Improves stability and target engagement.

• Oligonucleotide Research: For structure–activity relationship studies.

• Drug Development: Essential in designing stable, next-generation oligonucleotide drugs.

Storage and Handling:

• Storage: Store dry at –20 °C under inert atmosphere.

• Handling: Use anhydrous acetonitrile and standard phosphoramidite synthesis protocols.

This product provides the stability and enhanced performance specifically required for advanced oligonucleotide therapeutics and research.